Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ccRCC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT06775574
What this trial is testing

Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study

Who this might be right for
ccRCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 704
Large-scale testing (Phase 3)Study completedNCT00606632
What this trial is testing

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Who this might be right for
Renal Cell CarcinomaKidney Cancer
Heidelberg Pharma AG 226
Testing effectiveness (Phase 2)Looking for participantsNCT07389629
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Who this might be right for
Iparomlimab and TuvonralimabClear Cell Renal Cell CarcinomaNeoadjuvant Therapy
Sun Yat-sen University 25
Not applicableUnknownNCT06317298
What this trial is testing

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Who this might be right for
Renal Cell Carcinoma, Clear Cell, Somatic
Peking University First Hospital 36
Not applicableNo Longer AvailableNCT06090331
What this trial is testing

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Who this might be right for
Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Early research (Phase 1)Active Not RecruitingNCT04696731
What this trial is testing

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Who this might be right for
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Allogene Therapeutics 120
Testing effectiveness (Phase 2)Looking for participantsNCT06690697
What this trial is testing

Combination of Toripalimab and JS004 Therapy for ccRCC

Who this might be right for
Clear Cell Renal Cell Carcinoma
Fudan University 80
Early research (Phase 1)Ended earlyNCT06191796
What this trial is testing

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Who this might be right for
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Exelixis 25
Very early researchWithdrawnNCT06708936
What this trial is testing

KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study

Who this might be right for
Clear Cell Renal Cell Carcinoma (ccRCC)
Kousai Bio Co., Ltd.
Testing effectiveness (Phase 2)Active Not RecruitingNCT06964958
What this trial is testing

177LuPSMA in Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaKidney Cancer
Dana-Farber Cancer Institute 24
Large-scale testing (Phase 3)Active Not RecruitingNCT05239728
What this trial is testing

Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,800
Testing effectiveness (Phase 2)Looking for participantsNCT06613269
What this trial is testing

68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

Who this might be right for
Clear Cell Renal Cell Carcinoma
Peking Union Medical College Hospital 40
Early research (Phase 1)Ended earlyNCT04895748
What this trial is testing

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Who this might be right for
Carcinoma, Renal Cell
Novartis Pharmaceuticals 40
Early research (Phase 1)Active Not RecruitingNCT07000149
What this trial is testing

Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Who this might be right for
Advanced Clear Cell Renal Cell Carcinoma
AstraZeneca 9
Large-scale testing (Phase 3)Active Not RecruitingNCT04810078
What this trial is testing

Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

Who this might be right for
Clear Cell Renal Cell Carcinoma
Bristol-Myers Squibb 681
Not applicableLooking for participantsNCT07540260
What this trial is testing

CAIX PET/ CT Guided Radiation Therapy in CcRCC.

Who this might be right for
Radiation TherapyMetastatic Renal CancerRecurrent Renal Cell Cancer
Peking University First Hospital 70
Testing effectiveness (Phase 2)Ended earlyNCT01649180
What this trial is testing

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
PrECOG, LLC. 3
Testing effectiveness (Phase 2)Looking for participantsNCT07123090
What this trial is testing

Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Who this might be right for
Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell Carcinoma+3 more
Stephanie Berg 25
Not applicableLooking for participantsNCT06916624
What this trial is testing

Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)
The Affiliated Hospital of Qingdao University 120
Testing effectiveness (Phase 2)Study completedNCT00142415
What this trial is testing

Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer

Who this might be right for
Metastatic Renal Cell Carcinoma
Ludwig Institute for Cancer Research 26
Next Page